A clinical-stage biotechnology company developing gene therapies using adeno-associated virus (AAV) vectors. Its proprietary NAV Technology Platform is used both in internal drug programs targeting rare genetic diseases and through licensing agreements with pharmaceutical partners. Investors track t...
2 members of Congress have disclosed 3 trades in REGENXBIO Inc. (RGNX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2024-12-20 | Anna Paulina Luna | sell | $15K – $50K |
| 2019-11-08 | PETER WELCH | sell | $1K – $15K |
| 2019-10-22 | PETER WELCH | buy | $1K – $15K |